INFE.PA Compagnie Industrielle EURONEXT Pre-Market 21 Feb 2026: €71.00 pullback sets oversold bounce

We see INFE.PA stock trading at €71.00 pre-market on EURONEXT as of 21 Feb 2026 after a short-term pullback from the 50-day average. The move leaves a possible oversold bounce setup given the 3-month decline of -14.46% but a 6-month gain of +26.79%. Key fundamentals remain solid: EPS €6.35 and PE 11.18. Volume is light at 16 shares versus a 50-day average of 85, so price swings may amplify. As an AI-powered market analysis platform, Meyka AI flags a tactical rebound opportunity while noting liquidity and dividend data that need verification.

Price snapshot and market context for INFE.PA stock

INFE.PA stock is quoted at €71.00 on EURONEXT (Europe) with market cap €83,492,663 and 1,175,953 shares outstanding. Year range is €50.50 to €100.00. The stock sits below the 50-day average (€75.04) but above the 200-day average (€65.85), signalling a short-term pullback inside a longer-term uptrend. Sector peers in Industrials show a 1-week performance of +2.96%, supporting selective rebounds in engineering and construction names.

Technical view: why this is an oversold bounce setup

The tactical setup for an oversold bounce is simple: INFE.PA stock has retraced 5.40% versus its 50-day average and is down 14.46% over three months. Low trading volume (16 today, avg 85) increases the chance of sharp mean-reversion moves. The 200-day average at €65.85 offers a lower structural support level, while short-term resistance clusters near the 50-day at €75.04. Traders should watch intraday liquidity and spreads; small orders can move the price materially.

Fundamentals and valuation for INFE.PA stock

Compagnie Industrielle et Financière d’Entreprises SA reports EPS €6.35 and a trailing PE of 11.18, which reads as value-friendly versus many Industrials at an average PE near 25.35. Key balance metrics: cash per share €29.94, book value per share €23.84, and net debt to EBITDA strongly negative at -4.62, indicating net cash. Price-to-sales is 0.33 and EV/EBITDA is 1.96, both pointing to an economical valuation for the sector.

Dividend, payout and data notes for INFE.PA stock

Reported metrics show a dividend per share TTM of €11.33 and a dividend yield shown at 15.96% at current price. That yield appears unusually large relative to reported EPS €6.35 and a payout ratio listed at 0.20. This mismatch suggests the dividend line may include non-recurring distributions or requires verification in company filings. Investors should confirm dividend policy before relying on yield in income strategies.

Meyka AI grade, forecast and price-targets for INFE.PA stock

Meyka AI rates INFE.PA with a score out of 100: Score: 72.13 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year price of €74.29, a 3-year price of €83.65, and a 5-year price of €93.19. Compared with the current price €71.00, the 1-year forecast implies an upside of 4.63%. Forecasts are model-based projections and not guarantees.

Risk, liquidity and how traders should size INFE.PA stock positions

Primary risks are low liquidity (avg volume 85), episodic receivables cycle (DSO 152.94 days), and project execution in engineering & construction. Debt metrics are conservative: debt-to-equity 0.32 and net cash position by enterprise measures. For an oversold bounce approach, limit position sizes, use tight stop-losses near €65.85, and scale out toward €75.00–€80.00 if volume confirms the move.

Final Thoughts

INFE.PA stock at €71.00 presents a tactical oversold bounce candidate on EURONEXT on 21 Feb 2026. Short-term technicals show a pullback from the 50-day average while longer-term trend stays constructive above the 200-day average. Fundamentals support selective buying: EPS €6.35, PE 11.18, cash per share €29.94, and an EV/EBITDA of 1.96. Meyka AI’s forecast model projects €74.29 in one year, implying a modest 4.63% upside from today; three- and five-year projections extend upside to 17.83% and 31.29% respectively. Given thin volume (16) and payout data that require confirmation, treat positions as tactical trades not long‑only core buys. We recommend using small sizes, a stop near the 200-day average €65.85, and taking profits in the €75.00–€80.00 range if momentum confirms. Forecasts are model-based projections and not guarantees. For further intraday data and the official company site see Investing.com market context on Parrot and Investing.com market summary. Also view our INFE.PA page on Meyka for live updates and tools.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.